In:
Journal of Comparative Effectiveness Research, Becaris Publishing Limited, Vol. 12, No. 9 ( 2023-09)
Abstract:
Relapsing-remitting multiple sclerosis (RRMS) is the most common type of MS, an autoimmune disease that impacts the central nervous system, and is characterized by attacks (i.e., relapses) followed by complete or partial remissions. RRMS is associated with increased disability, costs, and reduced productivity due to disease progression. Early treatment with a high-efficacy therapy might improve outcomes and reduce costs. The study objective was to evaluate the costs and consequences of initial administration of the high-efficacy therapy ofatumumab, as well as after treatment with other commonly used first-line therapies, in patients with RRMS with active disease in Canada. What were the results? Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes versus commonly administered first-line therapies. What do the results of the study mean? Results suggest that a high-efficacy therapy, like ofatumumab, would be a valuable early treatment option for patients with RRMS.
Type of Medium:
Online Resource
ISSN:
2042-6305
,
2042-6313
DOI:
10.57264/cer-2022-0175
Language:
English
Publisher:
Becaris Publishing Limited
Publication Date:
2023
detail.hit.zdb_id:
2669725-7